Establishment Labs (NASDAQ:ESTA) Hits New 12-Month High – What’s Next?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price reached a new 52-week high on Monday . The company traded as high as $97.59 and last traded at $95.11, with a volume of 144133 shares traded. The stock had previously closed at $92.54.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ESTA shares. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a report on Monday. BTIG Research reissued a “buy” rating on shares of Establishment Labs in a research report on Monday, July 13th. Citigroup raised their price objective on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Finally, Mizuho boosted their price target on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus target price of $90.43.

Establishment Labs Trading Up 2.4%

The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The business’s 50 day moving average is $84.92 and its 200-day moving average is $73.57. The firm has a market cap of $2.79 billion, a P/E ratio of -63.62 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. During the same quarter last year, the company earned ($0.70) earnings per share. The company’s revenue was up 44.7% compared to the same quarter last year. As a group, analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 9.99% of the company’s stock.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently bought and sold shares of the company. KBC Group NV bought a new stake in shares of Establishment Labs in the 1st quarter valued at approximately $28,000. Kestra Advisory Services LLC bought a new position in Establishment Labs during the fourth quarter worth $47,000. Quarry LP acquired a new position in Establishment Labs in the third quarter worth $34,000. MV Capital Management Inc. acquired a new position in Establishment Labs in the fourth quarter worth $146,000. Finally, Osaic Holdings Inc. increased its stake in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.